Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.023
Sell
RSI(14)
41.478
Neutral
STOCH(KDJ)(9,3,3)
28.027
Buy
ATR(14)
0.270
Low Volatility
CCI(14)
-20.174
Neutral
Williams %R
60.099
Sell
TRIX(12,20)
-1.260
Sell
StochRSI(14)
100.000
Buy
Dermata Therapeutics Inc
DRMA2.370USD
+0.330+16.18%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.00MMarket Cap
0.16P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Dermata Therapeutics Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Dermata Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+261.01%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Dermata Therapeutics Inc Highlights
StrengthsRisks
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.08, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.82K shares, decreasing 2.63% quarter-over-quarter.
Financial Health
Currency: USD Updated: 2025-10-27No financial score is currently available for Dermata Therapeutics Inc. The Biotechnology & Medical Research industry's average is 6.92.
Score
Financials
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
Operational Efficiency
Growth Potential
Shareholder Returns
Dermata Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-10-27The current valuation score of Dermata Therapeutics Inc is 6.28, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.08, which is -85.61% below the recent high of -0.01 and -116.81% above the recent low of -0.18.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 278/501
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-10-27The current earnings forecast score of Dermata Therapeutics Inc is 8.00, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The average price target for Dermata Therapeutics Inc is 10.00, with a high of 10.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+261.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Dermata Therapeutics Inc
DRMA
1
CRISPR Therapeutics AG
CRSP
30
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-10-27The current price momentum score of Dermata Therapeutics Inc is 4.68, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.35 and the support level at 3.31, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.188
Buy
MA10
2.342
Buy
MA20
2.622
Sell
MA50
3.082
Sell
MA100
4.259
Sell
MA200
6.190
Sell
Institutional Confidence
Currency: USD Updated: 2025-10-27Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-10-27No risk assessment score is currently available for Dermata Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.56. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.55
VaR
--
240-Day Maximum Drawdown
+73.64%
240-Day Volatility
+267.37%
Return
Best Daily Return
60 days
+16.18%
120 days
+16.18%
5 years
--
Worst Daily Return
60 days
-16.73%
120 days
-16.73%
5 years
--
Sharpe Ratio
60 days
-2.80
120 days
-1.95
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+73.64%
3 years
+98.98%
5 years
--
Return-to-Drawdown Ratio
240 days
+1.32
3 years
-0.32
5 years
--
Skewness
240 days
+0.11
3 years
+4.06
5 years
--
Volatility
Realised Volatility
240 days
+267.37%
5 years
--
Standardised True Range
240 days
+14.45%
5 years
--
Downside Risk-Adjusted Return
120 days
-302.56%
240 days
-302.56%
Maximum Daily Upside Volatility
60 days
+97.68%
Maximum Daily Downside Volatility
60 days
+79.81%
Liquidity
Average Turnover Rate
60 days
+1.73%
120 days
+39.09%
5 years
--
Turnover Deviation
20 days
-99.66%
60 days
-98.81%
120 days
-73.00%
Peer Comparison
Biotechnology & Medical Research
Dermata Therapeutics Inc
DRMA
3.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Dermata Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Dermata Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Dermata Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Dermata Therapeutics Inc?
To generate the financial health score of Dermata Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Dermata Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Dermata Therapeutics Inc.
How do we generate the company valuation score of Dermata Therapeutics Inc?
To generate the company valuation score of Dermata Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Dermata Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Dermata Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Dermata Therapeutics Inc.
How do we generate the earnings forecast score of Dermata Therapeutics Inc?
To calculate the earnings forecast score of Dermata Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Dermata Therapeutics Inc’s future.
How do we generate the price momentum score of Dermata Therapeutics Inc?
When generating the price momentum score for Dermata Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Dermata Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Dermata Therapeutics Inc.
How do we generate the institutional confidence score of Dermata Therapeutics Inc?
To generate the institutional confidence score of Dermata Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Dermata Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Dermata Therapeutics Inc.
How do we generate the risk management score of Dermata Therapeutics Inc?
To assess the risk management score of Dermata Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Dermata Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Dermata Therapeutics Inc.
